Skip to content

Ketamine Use in Electroconvulsive Therapy

Ketamine Use in Electroconvulsive Therapy: Clinical, Cognitives and Neurotrophic Outcomes

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02012335
Enrollment
0
Registered
2013-12-16
Start date
2014-01-31
Completion date
2016-01-31
Last updated
2015-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

The purpose of this study is to determine whether combination of ketamine plus electroconvulsive therapy improves depressive symptoms decreasing cognitive side effects.

Detailed description

This study will compare the clinical response to brief pulse ECT with infusion of ketamine 0.5 mg/kg versus brief pulse electroconvulsive therapy with infusion of placebo (saline) in major depression. We also will compare levels of cognitive impairment among these groups, compare levels of quality of life among these groups, compare levels of BDNF among these groups. We also will study if levels of 25-hydroxyvitamin D are associated with cognitive impairment in subjects undergoing ECT.

Interventions

DRUGECT + Ketamine

Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patients with unipolar and bipolar depression from The Psychiatric Unit of Hospital de Clinicas de Porto Alegre (diagnosis will be established by the Structured Clinical Interview for DSM-IV Axis I)

Exclusion criteria

* Patients with dementia * History of addiction / abuse of psychoactive drugs * Other psychiatric diagnoses * Refusal to follow the study.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale (HAM-D) 17 changeBaseline, week 1, week 2, week 3, week 4, and at the end of hospital stay, an expected average of 5 weeks

Secondary

MeasureTime frame
Autobiographical Memory Test changeBaseline and at the end of hospital stay, an expected average of 5 weeks
Rey Auditory Verbal Learning Test changeBaseline and at the end of hospital stay, an expected average of 5 weeks
WAIS Digit Span changeBaseline and at the end of hospital stay, an expected average of 5 weeks
FAS verbal fluency changeBaseline and at the end of hospital stay, an expected average of 5 weeks
Stroop Test changeBaseline and at the end of hospital stay, an expected average of 5 weeks
Mini Mental Status Exam changeBaseline and at the end of hospital stay, an expected average of 5 weeks
WAIS VocabularyBaseline
Montgomery and Asberg Depression Rating Scale changeBaseline, week 1, week 2, week 3, week 4, and at the end of hospital stay, an expected average of 5 weeks
Brief Psychiatry Rating Scale changeBaseline, week 1, week 2, week 3, week 4, and at the end of hospital stay, an expected average of 5 weeks
Clinical Global Impression-Severity changeBaseline, week 1, week 2, week 3, week 4, and at the end of hospital stay, an expected average of 5 weeks
Trial Making Test changeBaseline and at the end of hospital stay, an expected average of 5 weeks

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026